Free-text search
Articles per year:
Content Types
-
AbbVie’s myeloma candidate hits both goals in Phase III
The pharmaceutical company Abbvie's etentamig met both primary endpoints in the Phase III CERVINO study in relapsed or refractory multiple myeloma.
-
She will lead Unilabs in the Nordics
Unilabs has appointed Ellen Gijsbers as General Manager Nordics.
-
IRLAB CEO to step down
Kristina Torfgård will step down as CEO of Swedish pharmaceutical company IRLAB Therapeutics in the first quarter of 2027, the company announced.
-
Novartis reshapes biologics business – 130 jobs at risk
Novartis is continuing to reshape its European operations. Around 130 jobs could now be cut in Basel as the pharmaceutical giant consolidates its biologics development activities and relocates parts of its manufacturing operations.
-
Chinese approval for Leqembi auto-injector
BioArctic’s partner Eisai has received approval in China for the subcutaneous auto-injector formulation of Leqembi as an initial treatment for early Alzheimer’s disease, according to a press release.
-
A turning point for personalized cancer vaccines – ”The field is moving quickly now”
The progress of a new personalised drug candidate for skin cancer is raising great hopes in the research community. ”It strengthens confidence in the entire class of neoantigen‑based vaccines”, says Sara Mangsbo, professor of cancer immunotherapy at Uppsala University.
-
Swedish‑developed CT scanner cleared in Europe: “Very exciting”
GE Healthcare’s photon‑counting computed tomography (PCCT) system, Photonova Spectra, has now received CE Mark, enabling the Swedish‑developed technology to be sold across the European market.
-
The newborn injection more parents are choosing to decline
A vitamin K injection has long been routine for newborn babies, protecting them against rare but potentially serious bleeding. But in the US, a growing number of parents are choosing to decline the injection – a trend also seen in Sweden.
-
BTK inhibitor shows efficacy in MS – without liver toxicity
A new MS treatment from Novartis has met its targets in two Phase III studies – without showing the liver-related side effects that have previously characterized the drug class.
-
Norwegian drug developer expands into other Scandinavian markets
After four years, NordicRWE has turned to Sweden and Denmark to broaden its business
-
Orexo CEO on settlement: “Very mixed feelings”
After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.
-
AstraZeneca combination shows promise in advanced lung cancer
AstraZeneca and China's Hutchmed have reported positive phase III results for a combination of their cancer drugs Tagrisso and Orpathys in advanced lung cancer.
-
Medtronic issues second recall after 184 serious patient injuries
Medtronic is recalling parts of its oesophageal pH monitoring system following reports that the capsule may fail to attach or detach from the delivery device as intended. A total of 184 serious patient injuries have been reported.
-
Sweden appoints its first professor of HTA
Susanna Wallerstedt has been appointed Sweden’s first professor of health technology assessment (HTA) at the University of Gothenburg and Sahlgrenska University Hospital. Her role will encompass research, education and clinical work, with a focus on advancing evidence-based healthcare.
-
Canada backs reimbursement for BioArctic’s Leqembi
Bioarctic's Leqembi receives positive reimbursement recommendation in Canada.
-
Eli Lilly to acquire Merida Biosciences for up to 2.9 billion dollars
US pharmaceutical company Eli Lilly has entered into a definitive agreement to acquire biotech company Merida Biosciences for up to 2.875 billion dollars in cash, including an initial payment and contingent milestone payments.
-
Elekta secures €100 million loan from EIB
Swedish radiation therapy company Elekta has secured a €100 million loan from the European Investment Bank (EIB).
-
Aqilion could be up for sale after receiving an indicative offer
Swedish biotech company Aqilion has received an indicative offer for all of its shares, potentially paving the way for a takeover of the company.
-
Lifecare acquires 80 percent of Ocean TuniCell
Medical technology company Lifecare has signed an agreement to acquire 80 percent of Ocean TuniCell, thereby gaining control of the company’s laboratory and production infrastructure in Bergen, including cleanrooms and quality systems.
-
“If we can’t import it, we want to make it ourselves”
In an unassuming industrial estate in Häggvik, north of Stockholm, outpatient pharmacy Atrimus RX runs its operations. Here, founder Nicky Nadem combines a global search for medicines available under special licence with a new venture into 3D-printed medicines – aiming to tackle shortages and give patients, particularly children, the right dose from the outset.
-
U.S. patent clears path for Elicera’s glioblastoma CAR‑T
Elicera Therapeutics announced on Friday that the company has received advance notice of the approval of a U.S. patent related to its CAR‑T cell candidate ELC‑401.
-
GSK’s potential blockbuster makes Swedish comeback
Following the withdrawal of its marketing authorisation and an earlier recommendation against its use, GSK’s Blenrep is making a comeback in Sweden. The Swedish New Therapies Council (NT-rådet) now recommends the drug from the second line of treatment for multiple myeloma.
-
FDA OKs new once-daily HIV combo pill
The U.S. Food and Drug Administration has approved a new once‑daily tablet from Gilead Sciences for the treatment of adults whose HIV infection has already been suppressed to very low levels.
-
Nykode raises NOK 286m to accelerate drug development
Norwegian biotech company Nykode Therapeutics has completed a private placement of approximately NOK 286m before costs.
BREAKING